Stephanie Davis
Stock Analyst at Barclays
(0.57)
# 4,105
Out of 5,182 analysts
98
Total ratings
31.34%
Success rate
-108.92%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Overweight | $210 → $225 | $198.02 | +13.62% | 8 | Feb 11, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $23.74 | +89.55% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $6.56 | -23.78% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $22.77 | +229.38% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.31 | +10.94% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.05 | +192.68% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $2.25 | +744.44% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $324.80 | -10.71% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $214.05 | -37.86% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $34.15 | +69.84% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $5.18 | -42.08% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $14.27 | -94.74% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $273.72 | -9.03% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $8.37 | +246.48% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $5.27 | +545.16% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $16.60 | +104.82% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $173.98 | +33.92% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $1.17 | +1,352.99% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $84.63 | -10.20% | 5 | Jun 7, 2022 |
Quest Diagnostics
Feb 11, 2026
Maintains: Overweight
Price Target: $210 → $225
Current: $198.02
Upside: +13.62%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $23.74
Upside: +89.55%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $6.56
Upside: -23.78%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $22.77
Upside: +229.38%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.31
Upside: +10.94%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.05
Upside: +192.68%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $2.25
Upside: +744.44%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $324.80
Upside: -10.71%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $214.05
Upside: -37.86%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $34.15
Upside: +69.84%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $5.18
Upside: -42.08%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $14.27
Upside: -94.74%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $273.72
Upside: -9.03%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $8.37
Upside: +246.48%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $5.27
Upside: +545.16%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $16.60
Upside: +104.82%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $173.98
Upside: +33.92%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $1.17
Upside: +1,352.99%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $84.63
Upside: -10.20%